Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H21N3O2 |
Molecular Weight | 287.3568 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCC1=CNC2=C1C=C(C[C@H]3COC(=O)N3)C=C2
InChI
InChIKey=ULSDMUVEXKOYBU-ZDUSSCGKSA-N
InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1
Molecular Formula | C16H21N3O2 |
Molecular Weight | 287.3568 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdfCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9154322
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9154322
Zolmitriptan (Zomig; formerly 311C90) is a novel 5-hydroxytryptamine (5HT)1B/1D receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura. The N-desmethyl metabolite also has high affinity for 5-HT1B/1D and moderate affinity for 5-HT1A receptors. Migraines are likely due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of Zomig for the treatment of migraine headache is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system, which result in cranial vessel constriction, and inhibition of pro-inflammatory neuropeptide release.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1983 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9154322 |
|||
Target ID: CHEMBL1898 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9154322 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | ZOMIG Approved UseINDICATIONS & USAGE Zolmitriptan is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use Only use zolmitriptan if a clear diagnosis of migraine has been established. If a patient has no response to zolmitriptan treatment for the first migraine attack, reconsider the diagnosis of migraine before zolmitriptan are administered to treat any subsequent attacks. Zolmitriptan is not indicated for the prevention of migraine attacks. Safety and effectiveness of zolmitriptan have not been established for cluster headache. Zolmitriptan is a serotonin(5-HT)1B/1D receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults (1) Limitations of Use: Use only after a clear diagnosis of migraine has been established (1) Not indicated for the prophylactic therapy of migraine (1) Not indicated for the treatment of cluster headache (1) Launch Date1997 |
|||
Palliative | ZOMIG Approved UseINDICATIONS & USAGE Zolmitriptan is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use Only use zolmitriptan if a clear diagnosis of migraine has been established. If a patient has no response to zolmitriptan treatment for the first migraine attack, reconsider the diagnosis of migraine before zolmitriptan are administered to treat any subsequent attacks. Zolmitriptan is not indicated for the prevention of migraine attacks. Safety and effectiveness of zolmitriptan have not been established for cluster headache. Zolmitriptan is a serotonin(5-HT)1B/1D receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults (1) Limitations of Use: Use only after a clear diagnosis of migraine has been established (1) Not indicated for the prophylactic therapy of migraine (1) Not indicated for the treatment of cluster headache (1) Launch Date1997 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
5.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
5.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
0.925 mg single, intravenous dose: 0.925 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
10 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
1.475 mg single, intravenous dose: 1.475 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
10.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
1.85 mg single, intravenous dose: 1.85 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
22.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
2.95 mg single, intravenous dose: 2.95 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
4.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
9.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
17.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
21.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
30.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
54.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
16.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
0.925 mg single, intravenous dose: 0.925 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
32.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
1.475 mg single, intravenous dose: 1.475 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
32.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
1.85 mg single, intravenous dose: 1.85 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
71.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
2.95 mg single, intravenous dose: 2.95 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
23.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
55.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.29 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.56 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
2.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.82 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
2.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
0.925 mg single, intravenous dose: 0.925 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
1.475 mg single, intravenous dose: 1.475 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
2.32 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
1.85 mg single, intravenous dose: 1.85 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.66 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595 |
2.95 mg single, intravenous dose: 2.95 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ZOLMITRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
75% |
unknown, unknown |
ZOLMITRIPTAN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
5 mg single, intranasal Highest studied dose |
unhealthy, 41.7 ± 10.4 Health Status: unhealthy Age Group: 41.7 ± 10.4 Sex: M+F Sources: |
Disc. AE: Taste abnormality, Migraine aggravated... AEs leading to discontinuation/dose reduction: Taste abnormality (0.4%) Sources: Migraine aggravated (0.4%) |
50 mg single, oral Overdose Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
Other AEs: Sedation... Other AEs: Sedation Sources: |
5 mg single, oral Recommended Dose: 5 mg Route: oral Route: single Dose: 5 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Arrhythmia, Cerebral hemorrhage... AEs leading to discontinuation/dose reduction: Arrhythmia Sources: Cerebral hemorrhage Subarachnoid hemorrhage Stroke Gastrointestinal ischemia Peripheral vasoconstriction Serotonin syndrome |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Migraine aggravated | 0.4% Disc. AE |
5 mg single, intranasal Highest studied dose |
unhealthy, 41.7 ± 10.4 Health Status: unhealthy Age Group: 41.7 ± 10.4 Sex: M+F Sources: |
Taste abnormality | 0.4% Disc. AE |
5 mg single, intranasal Highest studied dose |
unhealthy, 41.7 ± 10.4 Health Status: unhealthy Age Group: 41.7 ± 10.4 Sex: M+F Sources: |
Sedation | 50 mg single, oral Overdose Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Arrhythmia | Disc. AE | 5 mg single, oral Recommended Dose: 5 mg Route: oral Route: single Dose: 5 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
Cerebral hemorrhage | Disc. AE | 5 mg single, oral Recommended Dose: 5 mg Route: oral Route: single Dose: 5 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
Gastrointestinal ischemia | Disc. AE | 5 mg single, oral Recommended Dose: 5 mg Route: oral Route: single Dose: 5 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
Peripheral vasoconstriction | Disc. AE | 5 mg single, oral Recommended Dose: 5 mg Route: oral Route: single Dose: 5 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
Serotonin syndrome | Disc. AE | 5 mg single, oral Recommended Dose: 5 mg Route: oral Route: single Dose: 5 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
Stroke | Disc. AE | 5 mg single, oral Recommended Dose: 5 mg Route: oral Route: single Dose: 5 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
Subarachnoid hemorrhage | Disc. AE | 5 mg single, oral Recommended Dose: 5 mg Route: oral Route: single Dose: 5 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020768ap_zomig_phrmrp1.pdf#page=26 Page: 26.0 |
weak | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020768ap_zomig_phrmrp1.pdf#page=26 Page: 26.0 |
yes | yes (co-administration study) Comment: The increased exposure to zolmitriptan and 183C91 by cimetidine indicated that a reduction in the total daily recommended dose of zolmitriptan may be necessary when treating migraine patients who are taking nonspecific cytochrome P450 inhibitors or specific cytochrome 1A2 inhibitors. (https://pubmed.ncbi.nlm.nih.gov/18370509/) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020768ap_zomig_phrmrp1.pdf#page=26 Page: 26.0 |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/10553725/ Page: - |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/10553725/ Page: - |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/10553725/ Page: - |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/10553725/ Page: - |
weak | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/10553725/ Page: - |
weak | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/10553725/ Page: - |
weak | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/10553725/ Page: - |
weak | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020768ap_zomig_phrmrp1.pdf#page=25 Page: 25.0 |
yes | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020768ap_zomig_phrmrp1.pdf#page=25 Page: 25.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/22509823/ Page: - |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/17524230/ Page: - |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. | 1997 Oct |
|
Pharmacological analysis of the haemodynamic effects of 5-HT1B/D receptor agonists in the normotensive rat. | 1998 Jan |
|
Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers. | 1998 Jun |
|
[Mechanism of action of zolmitriptan]. | 1998 Oct |
|
Are triptans with enhanced lipophilicity used for the acute treatment of migraine associated with an increased consulting rate for depressive illness? | 2000 Oct |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine. | 2007 Sep |
|
In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. | 2008 Aug |
|
Triptans and troponin: a case report. | 2009 Jun 18 |
|
Prinzmetal-variant angina in a patient using zolmitriptan and citalopram. | 2010 Feb |
|
A new stability indicating HPLC method for related substances in zolmitriptan. | 2010 Jan |
|
Takotsubo syndrome (or apical ballooning syndrome) secondary to Zolmitriptan. | 2015 Mar-Apr |
Patents
Sample Use Guides
The recommended starting dose of ZOMIG (zolmitriptan) is 1.25 mg or
2.5 mg. The 1.25 mg dose can be achieved by manually breaking the functionally-scored 2.5 mg tablet in half. The maximum recommended single dose of ZOMIG is 5 mg.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10844127
Stimulation of a Ca(2+)-dependent K(+) current by zolmitriptan was investigated in C6 glioma cells stably expressing recombinant human 5-HT(1B) receptors. Outward K(+) currents (I(K)) were examined in non-transfected C6 glioma cells and in cells expressing cloned human 5-HT(1B) receptors using the patch-clamp technique in the whole-cell configuration. In C6 glioma cells expressing recombinant human 5-HT 1B) receptor, zolmitriptan increased I(K) in a concentration-dependent manner (maximum increase 16.3+/-7.8%, n=5, p<0.001) with a pD(2) value (geometric mean with 95% confidence intervals) of 7.03 (7.90-6.10). Zolmitriptan failed to elicit increases in I(K) in non-transfected C6 cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:12:08 GMT 2025
by
admin
on
Mon Mar 31 18:12:08 GMT 2025
|
Record UNII |
2FS66TH3YW
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN02CC03
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
||
|
NCI_THESAURUS |
C47794
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
||
|
NDF-RT |
N0000175763
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
||
|
NDF-RT |
N0000175765
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
||
|
WHO-ATC |
N02CC03
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
||
|
LIVERTOX |
1052
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
||
|
NDF-RT |
N0000175764
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000078816
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
PRIMARY | |||
|
2FS66TH3YW
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
PRIMARY | |||
|
60857
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
PRIMARY | |||
|
139264-17-8
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
PRIMARY | |||
|
7408
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
PRIMARY | |||
|
JJ-2
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
PRIMARY | |||
|
Zolmitriptan
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
PRIMARY | |||
|
60
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
PRIMARY | |||
|
760383
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
PRIMARY | |||
|
2869
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
PRIMARY | |||
|
ZOLMITRIPTAN
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
PRIMARY | |||
|
DB00315
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
PRIMARY | |||
|
10124
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
PRIMARY | |||
|
C47789
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
PRIMARY | |||
|
C089750
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
PRIMARY | |||
|
DTXSID8045933
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
PRIMARY | |||
|
135775
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB00181MIG
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
PRIMARY | |||
|
1727009
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
PRIMARY | |||
|
2FS66TH3YW
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
PRIMARY | |||
|
m11660
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
PRIMARY | Merck Index | ||
|
CHEMBL1185
Created by
admin on Mon Mar 31 18:12:08 GMT 2025 , Edited by admin on Mon Mar 31 18:12:08 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET -> AGONIST | |||
|
TARGET -> AGONIST |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT | |||
|
METABOLITE ACTIVE -> PARENT | |||
|
METABOLITE INACTIVE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||